Vaginal Microbiome Recovery After Bacterial Vaginosis Treatment Original paper
Researched by:
-
Divine Aleru
ID
Divine Aleru
I am a biochemist with a deep curiosity for the human microbiome and how it shapes human health, and I enjoy making microbiome science more accessible through research and writing. With 2 years experience in microbiome research, I have curated microbiome studies, analyzed microbial signatures, and now focus on interventions as a Microbiome Signatures and Interventions Research Coordinator.
-
Bacterial Vaginosis
Bacterial Vaginosis
Bacterial vaginosis (BV) is caused by an imbalance in the vaginal microbiota, where the typically dominant Lactobacillus species are significantly reduced, leading to an overgrowth of anaerobic and facultative bacteria.
-
Divine Aleru
Researched by:
-
Divine Aleru
ID
Divine Aleru
Microbiome Signatures identifies and validates condition-specific microbiome shifts and interventions to accelerate clinical translation. Our multidisciplinary team supports clinicians, researchers, and innovators in turning microbiome science into actionable medicine.
Divine Aleru
What Was Studied?
This observational study examined how the vaginal microbiota recovers after standard antibiotic treatment for bacterial vaginosis (BV). Researchers assessed changes in microbial composition before and after a five-day metronidazole treatment to determine how long it takes for the vaginal microbiome to return to a healthy state.
Who Was Studied?
The study included 30 women diagnosed with BV and 30 healthy women as controls. Researchers collected vaginal swabs before treatment (Day 1) and at follow-ups on Day 8 and Day 15 to compare microbiota recovery between the two groups. They analyzed microbial composition using 16S rRNA gene sequencing and measured BV status using Nugent scores.
Most Important Findings
Before treatment, BV-positive women had lower levels of Lactobacillus crispatus and Lactobacillus jensenii and a higher presence of Gardnerella vaginalis, Prevotella timonensis/bivia, and Atopobium vaginae. After metronidazole treatment, microbial diversity significantly decreased, and Lactobacillus iners became dominant (67.8% on Day 8). By Day 15, the vaginal microbiota of BV-treated women closely resembled that of healthy women. However, some BV-associated bacteria, including G. vaginalis and P. timonensis/bivia, began to re-emerge in a subset of participants.
The study also highlighted inconsistencies between Nugent scoring and microbiome sequencing results. While Nugent scores normalized in most BV-treated women by Day 8, sequencing data showed that bacterial communities still differed from those of healthy women, only stabilizing around Day 15. These findings suggest that clinical diagnostic methods may not fully capture microbiome recovery dynamics.
Implications of the Study
This study provides valuable insights into BV treatment outcomes and microbiome recovery. While metronidazole effectively reduces BV-associated bacteria, microbiome shifts continue for up to two weeks post-treatment. The dominance of L. iners after treatment raises questions about its role in BV recurrence. Future treatments should focus on restoring a L. crispatus-dominated microbiota, which is more protective against BV. The study also highlights the need for molecular-based diagnostics to better track microbiome recovery and predict BV recurrence.
Bacterial Vaginosis
Bacterial vaginosis (BV) is caused by an imbalance in the vaginal microbiota, where the typically dominant Lactobacillus species are significantly reduced, leading to an overgrowth of anaerobic and facultative bacteria.
Nugent Score
The Nugent Score is a standardized Gram stain-based scoring system used to diagnose bacterial vaginosis (BV) by assessing key bacterial morphotypes in vaginal samples. With its high specificity, it remains a gold standard in microbiome research, though its complexity and need for trained personnel make it less common in routine clinical practice.